Select publications

Azad N et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Presentation. ASCO 2006;Abstract 3004.

Brugarolas J. Renal-cell carcinoma — Molecular pathways and therapies. N Engl J Med 2007;356(2):185-7. No abstract available.

Casanovas O et al. Drug resistance by evasion of antiangiogenic targeting of VEGF
signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309. Abstract

Escudier B et al. Sorafenib in advanced clear cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Abstract

Motzer RJ et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

Rini BI et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refrac­tory metastatic renal cell carcinoma (mRCC). Proc ASCO 2006;Abstract 4522.

Ryan CW et al. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc ASCO 2006;Abstract 4525.

 

 

 

 

 

 

 

Home

Interviews
Brian I Rini , MD
- Select publications

Robert A Figlin, MD
- Select publications

MIchael B Atkins , MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office